Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
暂无分享,去创建一个
F. Rojo | J. Tabernero | J. García-Foncillas | A. Vivancos | C. Montagut | A. Antón | C. Camps | R. López | E. Díaz-Rubio | M. Benavides | E. Aranda | E. Elez | L. Muinelo-Romay | E. Jantus-Lewintre | Guillermo López | E. Élez
[1] Aneeya K. Samantara,et al. Advantages and Challenges , 2020 .
[2] Hwan-Mook Kim,et al. Perspective on Cancer Therapeutics Utilizing Analysis of Circulating Tumor Cells , 2018, Diagnostics.
[3] M. Delgado-Rodríguez,et al. Systematic review and meta-analysis. , 2017, Medicina intensiva.
[4] N. Normanno,et al. RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] J. Tabernero,et al. Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] O. Rosen,et al. 1473OEncouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST) , 2017 .
[7] I. Brandslund,et al. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. , 2017, The oncologist.
[8] M. Ychou,et al. Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] F. Coulet,et al. The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing , 2017, Molecular Diagnosis & Therapy.
[10] P. Laurent-Puig,et al. Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) , 2017, Clinical Cancer Research.
[11] C. la Vecchia,et al. European cancer mortality predictions for the year 2017, with focus on lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Albanell,et al. Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] R. Salazar,et al. Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[14] S. Fox,et al. Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing , 2017, Molecular oncology.
[15] D. Shelton,et al. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] W. Scheithauer,et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. , 2016, The Lancet. Oncology.
[17] R. Schilsky,et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Peng,et al. Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials , 2016, Scandinavian journal of gastroenterology.
[19] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] V. Moreno,et al. Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies , 2016, Molecular Cancer Therapeutics.
[21] R. Schilsky,et al. Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. , 2016, Journal of oncology practice.
[22] R. Luthra,et al. Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges , 2015, Cancers.
[23] Marc Peeters,et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.
[24] R. Strausberg,et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] C. Bokemeyer,et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.
[26] Chloe E Atreya,et al. Expanded RAS: refining the patient population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] E. Dequeker,et al. External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. , 2015, The oncologist.
[28] Sabine Tejpar,et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] P. Angenendt,et al. Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] M. Wiese,et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] Bruno Landi,et al. Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.
[32] James D. Murphy,et al. Colon cancer, version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.
[33] J. Tabernero,et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.
[34] S. Sleijfer,et al. KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue , 2013, International journal of cancer.
[35] A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens , 2012, British Journal of Cancer.
[36] H. Lee,et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.
[37] Yoko Yamamoto,et al. Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.
[38] K. Schaefer,et al. Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.
[39] Dongsheng Tu,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.
[40] S. Veronese,et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Frebourg,et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.
[42] J. Berlin,et al. The epidermal growth factor receptor as a target for colorectal cancer therapy. , 2005, Seminars in oncology.